CamilleNAbboudMD
Oncology • Saint Louis, MOHematologic Oncology
Professor of Medicine Section BMT and Leukemia
Dr. Abboud is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
Fl 7
Saint Louis, MO 63110Phone+1 314-747-1171- Is this information wrong?
Summary
- Dr. Camille Abboud is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 43 years. He also speaks multiple languages, including French and Arabic. He specializes in hematologic oncology and is experienced in hematologic oncology, acute myeloid leukemia, hairy cell leukemia, lymphoma, and cellular therapy including marrow and peripheral blood stem cell transplants and CAR-T treatment of lymphoma, myeloma and Acute Lymphoblastic Leukemia.
Education & Training
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1974 - 1976
American University of Beirut Faculty of MedicineClass of 1974
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2006 - 2025
NY State Medical License 1975 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Clinical Trials
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia Start of enrollment: 2005 Mar 01
- Oral Clofarabine for Acute Myeloid Leukemia Start of enrollment: 2009 Jan 01
- CC-4047 (Pomalidomide) for Graft vs. Host Disease Start of enrollment: 2009 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsCharacteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.Rima M Saliba, Amin M Alousi, Joseph Pidala, Mukta Arora, Stephen R Spellman, Michael T Hemmer, Tao Wang, Camille Abboud, Sairah Ahmed, Joseph H Antin, Amer Beitinjane...> ;Transplantation and Cellular Therapy. 2022 Oct 1
- 18 citationsLetermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille Abboud, Ravi Vij, Keith Stockerl-Goldstein, Iskra Pusic,...> ;Transplantation and Cellular Therapy. 2022 Aug 1
- 3 citationsDecitabine salvage for-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.Francesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, Christopher A Miller, Mary Elizabeth Percival, Geoffrey L Uy, Iskra Pusic, Meagan A Jacoby, Mathew J Christ...> ;Haematologica. 2022 Jul 1
- Join now to see all
Journal Articles
- Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell TransplantationM A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature
Abstracts/Posters
- Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND StudyCamille Abboud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...Camille Abboud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid LeukemiaCamille Abboud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Siteman Cancer Center to Open North St. Louis County Location July 1June 30th, 2017
Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationAugust 25th, 2023
Professional Memberships
- Member
Other Languages
- French, Arabic
Hospital Affiliations
Barnes-Jewish HospitalSaint Louis, Missouri
Siteman Cancer CenterSaint Louis, Missouri
Memorial Hospital BellevilleBelleville, Illinois
Memorial Hospital ShilohO Fallon, Illinois
Christian HospitalSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
